Catalyst Wire Dossier Catalyst Wire Dossier

TAK-788

· Millennium Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for TAK-788, covering 2020-01-29 to 2026-03-30. Get the full timeline:

Most recent: Clinical Trial Update: TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations [Phase 3]

See pricing